More children are testing positive for the flu as Californians continue to cough, hack and wheeze their way through an explosive influenza season. Influenza's rate of spread "is elevated in California ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

LITTLE ROCK, Ark. (KATV) — It’s a question so many women have asked: "If my mother had breast cancer, will I get it too?" But doctors say knowledge is power, and that power could save your life. UAMS ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...

Insurance covers some genetic tests, such as BRCA tests for breast cancer, if you meet certain requirements. Find Cheap Health Insurance Quotes in Your Area But there are about 70,000 different ...

—Dr. McArthur of University of Texas Southwestern Medical School discusses the ideal time to pursue genomic testing and how it may be able to help guide treatment. (1:45) The Current and Future Roles ...

Children born to women who carry pathogenic variants in mitochondrial DNA (mtDNA) are at risk for a range of clinical syndromes collectively known as mtDNA disease. Mitochondrial donation by ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

A microfluidic device barely larger than a U.S. quarter and developed by a Rutgers University-led team can detect rare genetic mutations from a single drop of blood. A team led by Rutgers ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...